RE: Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

Similar documents
Title: Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study

Title:Fulvic acid attenuates homocysteine-induced cyclooxygenase-2 expression in human monocytes

Endpoints for Stopping Treatment in UC

Faecal Calprotectin. Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS)

Mucosal healing: does it really matter?

Response letter. Dear Reviewers,

CLINICAL INSIGHTS 01

English Editing Samples

Title: Prevalence of sexual, physical and emotional abuse in the Norwegian Mother and Child Cohort Study

PEDIATRIC INFLAMMATORY BOWEL DISEASE

September 12, 2015 Millie D. Long MD, MPH, FACG

Implementation of disease and safety predictors during disease management in UC

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

Terumitsu; Nagayasu, Takeshi

I nflammatory bowel diseases (IBD) are chronic intestinal

Body: Re Should the threshold for definition of impaired fasting glucose be lowered?

Filiform polyposis of ulcerative colitis

Personalized Medicine in IBD: Where Are We in 2013

Title: A survey of attitudes toward clinical research among physicians at Kyoto University Hospital

Title: Dengue Score: a proposed diagnostic predictor of pleural effusion and/or ascites in adult with dengue infection

Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art

Title: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen

Evaluation of treatment effect in UC and CD (children)

Disease Monitoring. Symptoms Activity. No Symptoms No Activity. What is the Problem with Dogma? What are the FACTS

IBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease

Fujiya M, Saitoh Y, Watari J, Moriichi K, Kohgo Y.

MASSACHUSETTS GENERAL HOSPITAL HARVARD MEDICAL SCHOOL. January 4th, Dear Editors:

Title: Protocol-based management of older adults with hip fractures in Delhi, India: a feasibility study

Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis

Title: A Prospective Study of Dietary Selenium Intake and Risk of Type 2 Diabetes

Calprest NG. The most accurate test for calprotectin in stool. Extended range ELISA assay for calprotectin in stool. Lead by perfection

UNIVERSITY OF CALIFORNIA, LOS ANGELES

Title: Elevated depressive symptoms in metabolic syndrome in a general population of Japanese men: a cross-sectional study

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

Tips on Successful Writing and Getting Published Rita F. Redberg, MD, MSc, FACC, FAHA Professor of Medicine Editor, JAMA Internal Medicine

Author's response to reviews

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

Title: Childhood osteomyelitis-incidence and differentiation from other acute onset musculoskeletal features in a population-based study

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

DDW abstract review: Crohn s disease/ibd. Jesse Siffledeen Edmonton. May 26-28, 2017 Fairmont Chateau Lake Louise, Lake Louise, Alberta

Title: Survival endpoints in colorectal cancer. The effect of second primary other cancer on disease free survival.

Spectrum of Diverticular Disease. Outline

The Best of IBD at UEGW (Crohn s)

Title: Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature

Title: A Central Storage Facility to Reduce Pesticide Suicides- A Feasibility Study from India

Title:Continuity of GP care is associated with lower use of complementary and alternative medical providers A population-based cross-sectional survey

Common Questions in Crohn s Disease Therapy. Case

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease

The role of Surgery and Stomas in IBD

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Title: Effects of short-term heart rate variability biofeedback on long-term abstinence in alcohol dependent patients - a one-year follow up

Title:Determinants of high sensitivity cardiac troponin T elevation in acute ischemic stroke

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Author's response to reviews

Author's response to reviews

Title: Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report

Title: Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study

Title: Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases

Title: Persistent tumor cells in bone marrow of early breast cancer patients after primary surgery are associated with inferior outcome

Title: Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives

Title:BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

Title: Quality of life in childhood epilepsy with lateralized focus

Endoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Clinical Policy Title: Fecal biomarkers in inflammatory bowel disease

Title:Medically Unexplained Symptoms and the risk of loss of labor market participation - A prospective study in the Danish population

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

Title: Accuracy of calprotectin in evaluating sub- clinical inflammation in Ulcerative

Title:Modern contraceptive use among sexually active men in Uganda: Does discussion with a health worker matter?

Author's response to reviews

Author's response to reviews

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

INFLAMMATORY BOWEL DISEASE ORIGINAL CONTRIBUTIONS

Update in Pediatric IBD: 2018

Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis

As clinicians we would all agree that the goal for our

Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.

Title: Use of food labels by adolescents to make healthier choices on snacks: a cross sectional study from Sri Lanka

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

Author's response to reviews

Publishing Your Study: Tips for Young Investigators. Learning Objectives 7/9/2013. Eric B. Bass, MD, MPH

Title: Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women

Op#mizing)Management)in)IBD:) Mucosal)Healing)

February 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?

Colon Polyps: Detection, Inspection and Characteristics

Fecal Calprotectin Reliable, Novel, Noninvasive Biomarker. Bahar Allahverdi MD,TUMS,CMC Hospital Bahare Yaghmaie MD,TUMS,CMC Hospital

Literature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis

The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Transcription:

September 10, 2018 Professor Xue-Jiao Wang, MD Science Editor Editorial Office 'World Journal of Gastroenterology' RE: 40814 Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis Dear Professor Xue-Jiao Wang: Thank you for your e-mail of August 27, 2018 with regards to the above-mentioned manuscript. We also appreciate valuable suggestions of the reviewers. Based on your kind comment, we have made an extensive re-write of the text of the paper. We believe we have adequately responded to the comments. Attached please find a completely revised manuscript and a response to the issues raised by the reviewers. Your kind consideration of this revision for publication in WORLD JOURNAL OF GASTROENTERLOGY would be greatly appreciated. Sincerely, Jun Urushikubo, MD Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka, 020-8505, Japan. Phone: +81-19-651-5111 Fax: +81-19-652-6664 E-mail: urujun50@gmail.com

To the editor: 1. Please add postcode REPLY: The postcode has been added (Page 1, line 18). 2. Please submit Audio Core Tip. REPLY: We have submitted an audio file describing our final core tip. 3. Please provide all authors abbreviation names and manuscript title here. The abbreviation names should be the same as the copyright. World J Gastroenterol 2018; In press. REPLY: Abbreviations and names of all authors together with manuscript title have been added (Page 4, lines 15-17). 4. Please write Article Highlights. REPLY: Article Highlights have been added (Page 14, lines 1-31, Page 15, lines 1-3). To Reviewer 1: 1. How did you select that 50 patients who underwent colonoscopy? What was the reason? REPLY: Thank you for your comment. Because this study was a retrospective one, the indications for colonoscopy are not uniform. The indication for colonoscopy was clinically active disease or exacerbation of clinical symptoms in 14 subjects, assessment of therapeutic efficacy in 12 subjects, and surveillance for colorectal cancer in 24 subjects. The retrospective nature and the heterogeneity in the indication for colonoscopy have been stated (Page 7, paragraph 5, lines 24-28). The indications for colonoscopy have been added (Page 9, paragraph 5, lines 27-31). 2. The reference for all of the scoring systems should be given. REPLY: Thank you for your comment. In accordance with your comment, references for scoring systems have been added in the text of the paper and in

the reference list (Page 7, paragraph 2, line 6, page 7, paragraph 6, 31, page 18, ref.no 21,22,23). 3. What is the meaning of segmental colitis in patients with UC? This is either partially treated, CD or undetermined colitis and probably should have been excluded. REPLY: Thank you for your question. Segmental colitis refers to UC of rectal sparing type, and it is distinct from Crohn s disease and indeterminate colitis. This has been briefly stated with a reference in materials and methods (Page6, paragraph 3, lines 29-31, page 7, paragraph 1, line1, page18, ref.no 20). 4. Theoretically relation between albumin and FC should have been reverse. REPLY: Thank you for your comment. The level of FC was correlated with the levels of serum albumin (r=-0.447, P<0.001). Accordingly, there was a reverse correlation between FC value and serum albumin value. 5. In table 3 CRP is higher in non-relapsed. Very unlikely. REPLY: Thank you for your comment. Because there was only a little difference in CRP value between relapsed and non-relapsed patients, we think the result was a consequence by chance. 6. Although the concept of deep (histologic) mucosal healing is well accepted in CD but the evidence in UC is not that strong. The difference should be mentioned. REPLY: Thank you for your comment. We agree with the comment that histology has not been suggested as a target for the treatment of UC. In the treat-to-target concept for the management of UC, either histology or FC has not been suggested as a target. However, our observation strongly suggests that FC may be an alternative for histology. This has been stated in the discussion (Page 12, paragraph1, lines 6-11).

To Reviewer 2: 1. In figures 2 A, B, C the specificity is always less than 40% (the horizontal axis). Why in the text the authors reported specificity 62% (Fig 2A), 70% in fig 2B, 71% in fig 2C? REPLY: In figures 1 (previous Figure 2), the horizontal axis represents 1-specificity. Thus, there is not any discordance between the text and the figure as to the specificities. 2. What explanation is given of higher cut-off values than other studies? And How they explain no superiority of fecal calprotectin to traditional biomarkers such as CRP in predicting remission in UC? REPLY: Thank you for your comment. It has been reported that FC value measured by fluorescence enzyme immunoassay is higher than FC measured by ELISA [27]. We presume that this explains high cut-off values in our study. This has been stated in the discussion section (Page 11, paragraph 1, lines 5-12). As to the analysis of predictive value of FC, colonoscopy was not performed at the time of clinical remission. As a matter of fact, the relapse rate in our study population was considerably high. We thus speculate that we included subjects without mucosal healing who are prone to relapse. Such a bias seems to have resulted in no superiority of FC for the prediction of relapse. This has been discussed in the discussion section (Page 12, paragraph 2, lines 17-21). To Reviewer 3: 1. Which were the criteria for performing endoscopy? REPLY: Thank you for your comment. Because this study was a retrospective one, the indications for colonoscopy are not uniform. The indication for colonoscopy was clinically active disease or exacerbation of clinical symptoms in 14 subjects, assessment of therapeutic efficacy in 12 subjects, and surveillance for colorectal cancer in 24 subjects.

The retrospective nature and the heterogeneity in the indication for colonoscopy have been stated (Page 7, paragraph 5, lines 24-28). The indications for colonoscopy have been added (Page 9, paragraph 5, lines 27-31). 2. Results are interesting, but there is no discussion on the interaction with other inflammatory markers. A multivariate analysis of the predictive factors would be helpful, too. REPLY: Thank you for your kind comment. In order to respond to your comment, we added results of multivariate analysis in this revision. A logistic regression analysis including FC, CRP, WBC, ESR and platelet counts as co-variables failed to show any variables associated with endoscopic remission. Cox proportional hazard model failed to identify any variable predictive of relapse. However, a logistic regression analysis indicated that FC was an independent factor associated with histological remission (P=0.005). The application of logistic regression analyses and Cox proportional hazard model have been stated (Page 8, paragraph 3, lines 26-27, 31, page 9, paragraph 1, lines 1-2). Results of multivariate analyses have been indicated (Page 10, paragraph 1, lines 5-8, paragraph 2, lines 14-16, paragraph 3, lines 25-27). The significant association between FC and histology has been discussed (Page 11, paragraph 2, lines 17-21). 3. The rate of relapse is quite high 14% for 6 months of follow-up. Please explain. REPLY: Thank you for your comment. Because we did not perform colonoscopy at the time of clinical remission, and since the relapse rate in the study population was considerably high (14%), we presume that we included subjects without mucosal healing who are prone to relapses. Such a bias seems to have resulted in no superiority of FC for the prediction of relapse. This has been discussed in the discussion section (Page 12, paragraph 2, lines 13-21). 4. In discussion section there is a phrase "Our present study showed that a MES of 0 is associated with a lower risk of relapse and colectomy than a MES of 1

[21,22]. " Please rectify. REPLY: We apologize for a mistake in writing. The sentence has been changed (Page 11, paragraph 3, lines 25-27). 5. The value of FC=175 can orientate towards a possible relapse, but the sensitivity and specificity are below 70%, this seems not a good test. This should be underlined in the conclusion. REPLY: Thank you for your suggestion. As has been mentioned above, we discussed less value of FC for the prediction of relapse in our study population (Page 12, paragraph 2, lines 13-21). We also have added a need for further investigations for this topic. A sentence has been added in the final paragraph of the discussion (Page 13, paragraph 1, lines 4-5).